Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.8817 +0.0047 (+0.54%)
Streaming Delayed Price Updated: 10:42 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 198,889
Open 0.8840
Bid (Size) 0.8817 (6)
Ask (Size) 0.9000 (50)
Prev. Close 0.8770
Today's Range 0.8692 - 0.9000
52wk Range 0.6510 - 1.485
Shares Outstanding 407,265,944
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients 
From Amarin Corporation plc
Via GlobeNewswire

Performance

YTD
-0.84%
-0.84%
1 Month
-0.03%
-0.03%
3 Month
-34.69%
-34.69%
6 Month
+28.70%
+28.70%
1 Year
-36.11%
-36.11%

More News

Read More
Amarin Announces Results of Annual General Meeting of Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Via Benzinga
Why Amarin Stock Skyrocketed Today
Via The Motley Fool
Why Pharma Company Amarin Shares Are Zooming Today
Via Benzinga
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
From Amarin Corporation plc
Via GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
Why Amarin Stock Was Rocketing Higher on Wednesday
Via The Motley Fool
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
From Amarin Corporation plc
Via GlobeNewswire
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
From Amarin Corporation plc
Via GlobeNewswire
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is Amarin Stock Trading Lower After Q4 Earnings?
Via Benzinga
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Chairman & CEO Issue Letter to Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Falls 1%; Amarin Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On With Amarin Stock?
Via Benzinga
Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.